Avet Pharma Labs Inc. Announces Acquisition of 23 FDA-Approved ANDAs
East Brunswick, NJ, February 6, 2019 – Avet Pharma Labs Inc. (Avet) today announced that they have acquired a portfolio of 23 abbreviated new drug applications (ANDAs), covering 17 product families, all of which have been previously approved by the U.S. Food and Drug Administration (FDA). Financial terms were not disclosed. Of the newly acquired products, Avet and its parent company, Emcure Pharmaceuticals Ltd. had previously manufactured most of these products under a supply agreement with a third party, and Avet plans to launch all of these products into the U.S. market under a Avet label with immediate availability starting in Q2 2019 through its affiliate, Avet Pharmaceuticals Inc.